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INTRODUCTION 
 
There is growing evidence that C-reactive protein (CRP), a peripheral 
marker of inflammation, is also a marker of generalized atherosclerosis
1
. This 
relationship between inflammation and atherosclerosis make CRP a potential 
marker for prognosis after vascular events and a potential predictor of future 
vascular events. Acute phase proteins have been implicated to play roles both 
during acute and chronic inflammatory processes in different diseases including 
ischemic stroke 
2
                
The onset of cerebral ischaemia triggers a cascade of pro-inflammatory 
molecular and cellular events
3
. Clinical studies suggest that the strength of this 
acute response is important in early and late clinical outcomes, early clinical 
worsening, and extent of brain damage. Variables that are predictors of adverse 
stroke outcome include erythrocyte sedimentation rate, and levels of C-reactive 
protein (CRP), interleukin-6, tumour necrosis factor-α and intercellular 
adhesion molecule-1. Current data indicate that inflammation serves to fuel 
atherosclerosis and can act as the link between atherosclerosis and 
atherothrombosis.
4 
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Inflammatory factors play an important role in the pathogenesis of 
ischemic stroke. Acute phase proteins level such as a fibrinogen, CRP, 
ferritin increase after acute ischemic stroke. These findings support a possible 
role of an inflammatory stimulus in the acute ischemic stroke. 
 
The WHO has recently set international reference standard for the use of 
highly sensitive CRP assays. This has enhanced the usefulness of CRP as a 
reliable predictor of cardiovascular events. 
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AIM: 
 
1. To predict the functional outcome of acute ischemic stroke in relation 
with  hsCRP levels after 30 days 
2. To assess severity of stroke in association with hsCRP levels 
3. To determine its association with other risk factors. 
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EPIDIMEIOLOGY 
 
Globally, cerebrovascular disease (stroke) is the second leading cause of 
death. It is a disease that predominantly occurs in mid-age and older adults 
5
. 
WHO estimated that in 2005, stroke accounted for 5.7 million deaths world 
wide, equivalent to 9.9 % of all deaths. Over 85% of these deaths will have 
occurred in people living in low and middle income countries and one third will 
be in people aged less than 70 years 
 
Several population-based surveys on stroke were conducted from 
different parts of India. During the last decade, the age-adjusted prevalence rate 
of stroke was between 250-350/100,000 
6
. Recent studies showed that the age-
adjusted annual incidence rate was 105/100,000 in the urban community of 
Kolkata and 262/100,000 in a rural community of Bengal. The ratio of cerebral 
infarct to hemorrhage was 2.21. Hypertension was the most important risk 
factor. Stroke represented 1.2% of total deaths in India.  
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BURDEN OF STROKE IN INDIA(2004) 
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REVIEW OF LITERATURE 
 
World Health Organisation defines the clinical syndrome 
of ―stroke‖ as ‗rapidly developing clinical signs of focal (or global) disturbance 
of cerebral function with symptoms lasting 24 hours or longer or leading to 
death, with no apparent cause other than vascular origin.
7
 
 
Ischemic stroke is the most common stroke type, representing about 85% 
of all strokes. Ischemic stroke patients will typically present with the sudden 
onset of weakness, numbness, vision loss, diplopia, dysarthria, gait disorder, 
vertigo, aphasia, or disturbed level of consciousness. 
 
Focal cerebral ischemia differs fundamentally from global ischemia. In 
the latter state, if absolute, there is no cerebral blood flow of the entire brain and 
irreversible destruction of neurons occurs within 4 to 8 min at normal body 
temperature. 
 
 
14 
 
Table 3: Pathologic Classification of 
Stroke
 
 
 
CAUSES OF CEREBRAL ISCHEMIA AND INFARCTION 
 
Arterial Wall disorder 
• Atherthromboembolism 
• Intracranial small vessel disease (lipohyalinosis, microatheroma), 
• Trauma 
• Dissection 
15 
 
• Fibromuscular dysplasia 
• Congenital arterial anomalies 
• Moya Moya syndrome 
• Embolism from arterial aneurysm 
• Inflammatory vascular disease 
• Binswanger disease 
• Irradiation, infection 
• Embolism from the heart 
• Hematological disorders 
• Miscellaneous: 
Pregnancy 
OCP 
Drug Abuse 
Cancer 
Migraine 
Inflammatory Bowel Disease 
Homocystinemia 
Fabry‘s disease 
Mitochondrial Cytopathy 
Hypercalcemia 
Hypoglycemia 
Epidermal nevus syndrome 
Fat embolism 
16 
 
 
Thus it is evident that 
1) Cerebral infarction accounts for 80% of all strokes. 
2) Atherothromboembolism of cerebral arterial supply is the cause in about 50% 
of the cases of cerebral infarction 
 
RISK FACTORS 
Table4: RISK FACTORS 
9
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ATHEROSCLEROSIS: 
  
Laboratory and clinical evidence has demonstrated 
that  atherosclerosis is not simply a disease of lipid deposits. Rather, systemic 
inflammation also plays a pivotal role in atherothrombotic inception and 
progression. Mononuclear cells, macrophages, and T lymphocytes are 
prominent in atheromatous plaques in the arterial wall. Current knowledge, 
however, suggests that the CRP concentration might reflect the vulnerability of 
the atheromatous lesion and the likelihood of a plaque to rupture.
10,11,12
 
  The development of high sensitivity CRP (hs-CRP) assays has 
been instrumental in exploration of the role of this acute phase reactant in 
predicting first cardiovascular and cerebrovascular events. 
Accumulating data suggest that arterial tissues can produce CRP, with 
CRP and complement m-RNA being substantially upregulated in 
atherosclerotic plaque. Thus CRP may serve as an endogenous activator of 
complement in atheroma. 
13
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PREDICTORS OF STROKE OUTCOME 
 
I) Demographic factors: 
1. Age: 
Age is one of the major factors that negatively influence the outcome for 
patients with ischemic stroke 
14
. Older patients are less likely to recover than 
younger patients with similar sized infarcts. 
2. Gender: 
Some studies have shown male sex associated with poorer outcome 
whereas other studies have shown no difference. The explanation for this may 
be hormonal
15
. Estrogen seems to be an important mediator of improved 
outcome after ischemic brain injury. 
3. Race/Ethnicity: 
Although it is well understood that the incidence of stroke varies 
among races and ethnicities, there is no significant difference in the outcome 
between groups
16
. 
 
II) Cerebrovascular risk factors: 
1. Previous stroke and atrial fibrillation: 
Strokes in patients with previous stroke and atrial fibrillation are 
usually more severe, more disabling and associated with a higher moratlity. 
 
19 
 
 
III) Clinical findings: 
1. Level of consciousness and gaze deviation: 
Initial level of consciousness is an important predictor with decreased 
level of consciousness predicting poor outcome
17
. The presence of gaze 
deviation is associated with poor outcome. 
2. Blood Pressure: 
Abnormal blood pressure may influence outcome. Clinical studies of 
blood pressure reduction have shown a decrease in cerebral blood flow to the 
infarcted area
18
. On the contrary, excessively elevated blood pressure has 
negative long term effects on blood brain barrier function. 
 
3. Temperature: 
For each one degree celsius increase in body temperature, the relative 
risk of poor outcome rises two fold
19
. This may be due to the increased 
concentration of excitotoxic neurotransmitters present. Elevated temperature 
(>37.50C) was an independent predictor of large volume infarct and higher 
neurological deficit when it occurred in the first 24 hours after first stroke onset. 
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IV) Laboratory findings: 
1. Glycine and glutamate: 
High glycine or glutamate levels strongly correlated with large infarct 
size and severe neurological deficits
20
. 
2. S-100: 
Increased serum levels of S-100 correlate with neurologic outcome. 
3. Neuron-specific enolase: 
This enzyme has been shown to increase in acute stroke. 
4. Serum Glucose: 
Hyperglycemia is associated with increased morbidity and mortality
21
. 
Hyperglycemia seems to produce its detrimental effects by causing a profound 
cellular acidosis. Clinical studies have shown an association between 
hyperglycemia and cerebral edema. 
 
Role of Inflammation in Atherosclerosis 
Inflammation plays a major role in all phases of atherosclerosis. Stable 
plaques are characterized by a chronic inflammatory infiltrate, whereas 
vulnerable and ruptured plaques are characterized by an ‗‗active‘‘ inflammation 
involved in the thinning of the fibrous cap, predisposing the plaque to rupture
22.
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SERUM MARKERS CORRELATED WITH PLAQUE 
INFLAMMATION 
 
Traditional biomarkers for cardiovascular risk include LDL cholesterol 
and glucose. However, 50% of heart attacks and strokes occur in individuals 
who have normal LDL cholesterol levels, and 20% of major adverse events 
occur in patients with no accepted risk factors
23
 
 
PROPOSED BIOMARKERS FALL INTO 9 GENERAL 
CATEGORIES 
24
 
 
1. inflammatory markers 
2. markers of plaque erosion, 
3.markers of thrombosis 
4. lipid-associated markers 
5. markers of endothelial dysfunction  
6.oxidative stress 
7. metabolic markers 
8. markers of neovascularisation 
9. genetic markers. 
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Markers of Inflammation 
 
CRP is a circulating pentraxin that plays a major role in the human innate 
immune response 
25 
and provides a stable plasma biomarker for low-grade 
systemic inflammation. CRP is produced predominantly in the liver as part of 
the acute-phase response. However, CRP is also expressed in smooth muscle 
cells within diseased atherosclerotic arteries and has been implicated in multiple 
aspects of atherogenesis and plaque vulnerability, including the expression of 
adhesion molecules, the induction of NO, altered complement function, and 
inhibition of intrinsic fibrinolysis
26
. CRP is considered to be an independent 
predictor of unfavourable cardiovascular events in patients with atherosclerotic 
disease. 
 
Among patients with stable angina and established coronary artery 
disease (CAD), plasma levels of hs-CRP have consistently been associated with 
the risk of recurrent cardiovascular events 
27
.Similarly, in the presence of acute 
coronary ischemia, levels of hs-CRP are predictive of a high risk of vascular 
events even if troponin levels are not detectable, suggesting that inflammation is 
associated with plaque vulnerability even in the absence of detectable 
myocardial necrosis
28
. Despite these data, the most relevant use of hs-CRP 
remains in the setting of primary prevention. To date, over 2 dozen large-scale 
prospective studies have shown baseline levels of hs-CRP to independently 
predict future myocardial infarction, stroke, death from cardiovascular 
23 
 
disease, and peripheral arterial disease
29.
Data available through 2002, the 
Centers for Disease Control and Prevention and the American Heart Association 
endorsed the use of hs-CRP as an adjunct to global risk prediction, particularly 
among individuals with intermediate risk 
30
. 
  
Metabolic Markers 
Insulin and glucose are classic metabolic markers of insulin resistance. 
Recent research has focused on adipokines that may be involved in 
atherogenesis, including leptin and resistin.
31 
Lipid Markers 
Lipid markers, in addition to the classic LDL and highdensity lipoprotein 
(HDL) cholesterol, include OxLDL cholesterol, small dense LDL cholesterol, 
lipoprotein (a) [Lp(a)], and lipoprotein-associated phospholipase A2 (Lp-
PLA2).
32
 
At present, aside from imaging modalities, such as ultrasonography and 
MRI, and local temperature probes that could help to identify vulnerable 
plaques, highly sensitive inflammatory circulating markers, such as hs-CRP, 
cytokines, PAPP-A, and pentraxin 3 are currently the best candidates for diffuse 
active plaque detection.
33
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C-Reactive Protein (CRP) 
CRP, named for its capacity to precipitate the somatic C-polysaccharide 
of Streptococcus pneumoniae, was the first acute-phase protein to be described 
and is an exquisitely sensitive systemic marker of inflammation and tissue 
damage. It is a 23- KDa protein 
34 
Other acute-phase proteins include proteinase inhibitors and coagulation, 
complement, and transport proteins, but the only molecule that displays 
sensitivity, response speed, and dynamic range comparable to those of CRP is 
serum amyloid A protein (SAA). 
Function: 
CRP is a member of the class of acute phase reactants. It is thought to 
assist in complement binding to foreign and damaged cells and affect the 
humoral response to disease. It is believed to play an important role in innate 
immunity, as an early defense system against infection. 
 
Diagnostic Use: 
CRP is used mainly as a marker of inflammation. Measuring and charting 
CRP values can prove useful in determining disease processes or the 
effectiveness of treatment 
 
25 
 
Circulating CRP concentration 
In healthy young adult volunteer blood donors, the median concentration 
of CRP is 0.8 mg/l, the 90th centile is 3.0 mg/l, and the 99th centile is 10 mg/l , 
but, following an acute-phase stimulus, values may increase from less than 50 
μg/l to more than 500 mg/l, that is, 10,000-fold. Plasma CRP is produced only 
by hepatocytes, predominantly under transcriptional control by the cytokine IL-
6, although other sites of local CRP synthesis and possibly secretion have been 
suggested.
35
De novo hepatic synthesis starts very rapidly after a single stimulus, 
serum concentrations rising above 5 mg/l by about 6 hours and peaking around 
48 hours. The plasma half-life of CRP is about 19 hours and is constant under 
all conditions of health and disease, so that the sole determinant of circulating 
CRP concentration is the synthesis rate, which thus directly reflects the intensity 
of the pathological process(es) stimulating CRP production.
36 
Structure and phylogeny of CRP 
CRP belongs to the pentraxin family of calcium-dependent ligand-
binding plasma proteins, the other member of which in humans is serum 
amyloid P component (SAP). The human CRP molecule (Mr 115,135) is 
composed of five identical nonglycosylated polypeptide subunits (Mr 23,027), 
each containing 206 amino acid residues. The protomers are noncovalently 
associated in an annular configuration with cyclic pentameric symmetry. 
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Ligand binding and biological role of CRP 
Human CRP binds with highest affinity to phosphocholine residues, but it 
also binds to a variety of other autologous and extrinsic ligands, and it 
aggregates or precipitates the cellular, particulate, or molecular structures 
bearing these ligands. Autologous ligands include native and modified plasma 
lipoproteins , damaged cell membranes , a number of different phospholipids 
and related compounds, small nuclear ribonucleoprotein particles , and 
apoptotic cells.
37,38,39
 
Atherosclerosis and inflammation 
Chronic systemic, nonvascular inflammation is known to be 
proatherogenic in general, and acute systemic inflammatory episodes are 
strongly associated with atherothrombotic events. The increased production of 
CRP that predicts atherothrombotic events may therefore reflect inflammation 
elsewhere in the body 
There is a strong positive association between base-line CRP 
concentration and BMI , and weight loss lowers the CRP value 
40.
 Raised base-
line CRP values are also associated with many features of the insulin resistance 
or metabolic syndrome, up to and including frank diabetes mellitus. Indeed, 
CRP production predicts the development of type 2 diabetes independently of 
traditional risk factors 
41,42 
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Binding of CRP to lipids, especially lecithin (phosphatidyl choline), and 
to plasma lipoproteins has been known for over 60 years, but the first 
suggestion of a possible relationship to atherosclerosis came when we 
demonstrated that aggregated, but not native, nonaggregated, CRP selectively 
bound only LDL and some VLDL from whole serum. However, native CRP 
does bind to oxidized LDL  and to partly degraded LDL, as found in 
atheromatous plaques, and then activates complement. This CRP could promote 
complement activation and thus inflammation in the plaques, and there is 
experimental evidence supporting a possible role of complement in 
atherogenesis.
43,44
 CRP has also been reported to stimulate tissue factor 
production by peripheral blood monocytes in vitro and could thereby have 
important procoagulant effects . Other studies show a variety of effects in cell 
cultures exposed to CRP, including, for example, increased expression of 
adhesion molecules, and modulation of NO synthesis. 
CRP may have significant proinflammatory effects, and that, by binding 
to ligands exposed on cells or other autologous structures as a result of 
infection, inflammation, ischemia, and other pathologies, and triggering 
complement activation, it may exacerbate tissue damage, leading to more severe 
disease. The excellent correlation of circulating CRP concentrations with the 
severity, extent, and progression of many different pathologies, and the 
prognostic significance of these associations, are consistent with CRP not just 
being a marker of disease but also contributing to pathogenesis.
45 
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HIGH SENSITIVITY CRP (hs-CRP) 
In the late 1990s, high sensitivity CRP assays became available, allowing 
assessment of serum concentrations at the lower end of its distribution. In the 
subsequent years, hs-CRP levels far beneath the cut-off  value, indicative of an 
immediate-phase response, predicted the risk of cardiovascular, cerebrovascular 
disease, diabetes mellitus, and cognitive impairment. 
46,47
 
Normal reference range: 0.02 to 8.0 mg/L 
 
 
ROLE OF ACUTE PHASE REACTANTS IN ACUTE ISCHEMIC 
STROKE 
Acute phase proteins level such as a fibrinogen, CRP, ferritin increase 
after acute ischemic stroke. These findings support a possible role of an 
inflammatory stimulus in the acute ischemic stroke 
 
Fibrinogen: 
Fibrinogen is a well known acute phase protein and risk factor for 
myocardial infarction and stroke. High fibrinogen levels represent an acute 
phase response in early acute stroke. Fibrinogen is involved in primary 
29 
 
haemostasis, platelet aggregation, and leukocyte-endothelial cell interactions 
and is the major determinant of whole blood and plasma viscosity.
48
 
Ferritin: 
It is suggested that high serum ferritin levels within the first day of 
hospitalization for an acute ischemic stroke are related to poor 
prognosis.Oxidative metabolism during ischemic stroke together with high iron 
content in the brain synergise to increase the oxidative damage. High plasma 
ferritin, as a measurement of iron stores, and high cerebrospinal fluid ferritin 
have been related to poor outcome in stroke patients.
49 
 
CRP: 
High levels of hs-CRP are associated with adverse cardiovascular and 
cerebrovascular events. High CRP predicts the risk of carotid stenosis; first 
stroke and post stroke mortality. 
 
CRP AND ISCHEMIC STROKE 
Elevated plasma CRP concentrations are also associated with an 
increased risk of cerebrovascular events and an increased risk of fatal and 
nonfatal cardiovascular events in ischemic stroke patients. Determination of 
plasma CRP concentrations could be used as an adjunct for risk assessment in 
primary and secondary prevention of cerebrovascular disease and be of 
30 
 
prognostic value. CRP is as an independent predictor of cerebrovascular events 
in at-risk individuals and ischemic stroke patients. 
  The 'Bergen stroke study' prospectively studied 498 patients with 
ischemic stroke who were admitted within 24 hours after the onset of 
symptoms. CRP and NIH stroke scale (NIHSS) were measured at the time of 
admission. Short-term functional outcome was measured by modified Rankin 
scale (mRS) and Barthel ADL index (BI) 7 days after admission. Patients were 
followed for up to 2.5 years for long-term mortality and future vascular events 
data. The median CRP at admission was 3 mg/L. High CRP was associated with 
high NIHSS (p= 0.01) and high long-term mortality (p < 0.0001). After 
adjusting for confounding variables, high CRP remained to be associated with 
high NIHSS (p = 0.02) and high long-term mortality (p =0.002). High CRP was 
associated with poor short-term functional outcomes (mRS > 3; BI < 95). 
Admission CRP is associated with stroke severity and long-term mortality when 
measured at least 24 hours after onset. There is a crude association between 
high CRP and short term functional outcome which is likely secondary to stroke 
severity. CRP is an independent predictor of long-term mortality after ischemic 
stroke. Our study in ischemic stroke patients shows that a high CRP at 
admission is associated with more severe stroke, cardio-embolic etiology, poor 
functional outcome and high mortality. After adjusting for the effect of 
confounding factors, high CRP remained to be associated with more severe 
stroke and high mortality.
2
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FRAMINGHAM STUDY: 
To address the baseline CRP level and the risk of subsequent stroke 
events, the measurement of CRP was done in the Framingham study original 
cohort who were free of stroke or TIA at the time of their 1980 to 1982 clinical 
examination and related the baseline CRP plasma generation to the incidence of 
first stroke or TIA in these subjects during a 12 to 14 years follow up – men 
with the higher baseline CRP values had twice the risk of ischemic stroke and 
women with highest CRP level had a 5-fold increase in risk of any vascular 
event and a 7-fold increase in risk of the comorbid outcome of myocardial 
infarction or stroke. The data derived from this study demonstrated a graded 
increase in the incidence of ischemic stroke and TIA with increased levels of 
CRP.
50 
The Rotterdam study shows that although high CRP is associated with the 
risk for future stroke, it is not useful for individual stroke prediction 
Di Napoli et al concluded that there is insufficient evidence to justify the 
routine use of CRP for either primary or secondary risk stratification for 
cerebrovascular disease alone
51
 
Another study conducted by Winbeck K 
52 
and his colleagues investigated 
the impact of early serial CRP measurements in hyper-acute ischemic stroke on 
long-term outcome. One hundred twenty-seven consecutive patients without 
thrombolysis with a first ischemic stroke no more than 12 hours after symptom 
onset were examined. Serial CRP measurements were done at admission (CRP 
1), within 24 hours (CRP 2), and within 48 hours (CRP 3) after symptom onset. 
32 
 
In addition to several cerebrovascular risk factors, the 1-year outcome and the 
lesion volumes of initial diffusion-weighted images were determined. The CRP 
level measured within 12 hours after symptom onset of an acute ischemic stroke 
was not independently related to long-term prognosis. In contrast, a CRP 
increase between 12 and 24 hours after symptom onset predicted an 
unfavourable outcome and was associated with an increased incidence of 
cerebrovascular events. 
Ufuk Emry and his colleagues conducted a study to determine the 
influence of fibrinogen, CRP and other acute phase reactants in acute
53 
ischemic 
stroke in acute period (first 24 to 72 hours). Forty-three patients (23 female, 20 
male) who have been diagnosed as acute ischemic stroke, in Neurology 
department of Ankara Hospital, between June 2001 and December 2001 were 
included in this study. He concluded that the fibrinogen and CRP have a close 
relationship as inflammatory markers in the acute phase of ischemic stroke. In 
this study, which supports the previous ones, it has been found out that CRP 
levels in the patient were higher than in the control group levels. There was 
higher CRP level in the patients whose clinical health was poor and had high 
Stroke Severity Scale. 
 
Another study conducted by Mitchell SV Elkind et al also showed that 
levels of hs-CRP are higher in stroke patients than in stroke-free subjects.
54
 
Levels of inflammatory biomarkers associated with atherosclerosis, including 
hs-CRP, appear to be stable for at least 28 days after first ischemic stroke. This 
33 
 
study also found an association of post-stroke levels of hs-CRP with smoking 
and stroke severity. 
 
Muir KW et al in his study found that hs-CRP levels above 10.1mg/L 
when measured within 72 hours of stroke predicted mortality over 4 years102. 
Others found that the measurement of CRP at 24 or 48 hours, but not at 
admission, also predicted outcome99. In one study, hs-CRP levels ≥ 15 mg/L at 
discharge were associated with occurrence of a new vascular event or death at 1 
year. hs-CRP levels in the highest quintile measured at least 3 months after a 
first ischemic stroke or TIA were associated with an increased risk of 
subsequent stroke or MI in another study 
Another study was conducted by Yusuf Tamam et al to show the changes 
in plasma levels of six APPs (i.e., haptoglobin, ceruloplasmin, hs-CRP, 
fibrinogen, complement 3 and complement 4 during the first 10 days after acute 
ischemic stroke. He concluded that the peak levels of APPs were higher in the 
AIS group than the control group (p < 0.0001)1. After stroke, hs-CRP, C3 and 
fibrinogen reached their highest values on the third day. The plasma levels of 
hs-CRP correlated positively with other five APPs studied (p < 0.05). His 
findings supported the importance of inflammatory processes after stroke. He 
suggested that the differences in levels of APPs could be used in predicting the 
outcome of ischemic stroke patient. 
Elevated hs-CRP levels are shown to be strongly associated with the 
extent of the atherosclerosis in the carotid arteries. The relationship between the 
34 
 
increased serum hs-CRP levels and the atherosclerosis in the carotid arteries 
was found to be independent from the other known risk factors for the 
atherosclerosis. 
Higher CRP concentration was an independent predictor of mortality 
together with age and the severity of the stroke on the National Institute of 
Health Stroke Scale (Muir K. W. et al., 1999). In the same study, it was 
proposed that the CRP concentration was an independent predictor of the 
survival after the ischemic stroke which was consistent with the role of the 
inflammation in acute ischemic stroke, as well as with the hypothesis that 
elevated CRP might predict the future cardiovascular mortality Moreover in one 
study conducted in an elderly population without pre-existing stroke, it has been 
demonstrated that elevated CRP concentration was an independent risk factor 
for future ischemic stroke over 10 years of follow-up. 
 
High-sensitivity CRP serum level predicts further intracranial large-artery 
occlusive disease-related and any major ischemic events in patients with first-
ever TIA or stroke with intracranial large-artery occlusive disease. In the study 
conducted by Arenillas JF, Alvarez-Sabín J, Molina CA 2003,it was shown that 
Admission inflammatory markers  have long-term prognostic implications in 
patients with acute ischemic neurological events. These findings are relevant in 
view of the new therapeutic interventions now available for reducing the 
inflammatory response.Study by anuk in 2002. 
35 
 
CRP formerly considered solely an excellent biomarker of inflammation, 
is now viewed as a direct contributor in atherosclerosis. Recent evidences have 
emerged implicating CRP directly in atherogenesis. CRP has been found in 
human atherosclerotic plaque and CRP has been shown to cause endothelial cell 
dysfunction
55
 
It must be stressed that CRP, because of its analytical and biological 
properties and the large amount of available data, is the only inflammatory 
marker accepted for clinical use. hs-CRP not only predicts future  
cardiovascular events but can also be used to target therapeutic interventions. 
 
Levels of hs-CRP < 1, 1 -3 and >3 mg/L correspond to lower, moderate 
and higher risk of cardiovascular events at all levels of Framingham Risk Score 
and at all levels of metabolic syndrome. 
 Inflammation plays a critical
 
role in the development of vascular disease, 
and increased levels
 
of the inflammatory biomarkers, lipoprotein-associated 
phospholipase
 
A2 (Lp-PLA2), and high-sensitivity C-reactive protein (hs-CRP)
 
have been shown to be associated with an increased risk for
 
ischemic stroke.
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Inflammatory biomarkers, especially hsCRP, may allow improved 
prediction of the risk of stroke in primary and secondary stroke prevention. 
Modalities to reduce inflammation are becoming available that may help to 
modify this risk. Further studies, however, are needed before inflammatory 
markers become a routine part of the evaluation of stroke patients 
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MATERIALS AND METHODS 
Setting: Medical ward, K.A.P.V.Govt. Medical College, 
AGM. Govt. Hospital, Trichy 
Study design: 
Prospective hospital based study. 
Period of study: 
January 2010 to Oct 2010 
Inclusion criteria: 
1. All patients who presented within 48 hours of onset of stroke and who gave 
informed consent to participate in the study were included. 
EXCLUSION CRITERIA: 
1. Hemorrhagic stroke 
2. Age > 70 yrs 
3. NSAID INTAKE 
4. Connective tissue disorder/arthritis 
5. Recurrent stroke 
6. Active infections 
7. Ischaemic heart disease/ Coronary heart disease  
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Study method: 
A total of 50 patients who presented with acute ischemic stroke were 
enrolled into the study. That the stroke was an ischemic one was confirmed by 
CT scan. As soon as the patients were admitted within 48 hours of onset of 
stroke, serum samples were taken for hs-CRP estimation. Serum hs-CRP levels 
were also estimated in fifty normal patients (without any evidence of acute 
infection, neoplasm, rheumatic heart disease, collagen vascular disease, 
hypertension, DM, IHD) and was found to be within normal limits. Standard 
guidelines for the treatment of acute ischemic stroke were followed. None of the 
patients received any thrombolytic treatment. 
CRP and NIH stroke scale (NIHSS) were measured at the time of 
admission. Short-term functional outcome was measured by modified 
Rankin scale (mRS) and 30 days after admission. 
The NIH stroke score (NIHSS) was assessed  at the time of admission. 
The NIHSS was categorized as 0–7, 8– 14  
Patients with score of 0,1and 2 were included in the good outcome and 
patients with score of 3,4,5 and 6 were included in the poor outcome category. 
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Definitions followed in the Study: 
 
1.Stroke 
 
Stroke (as defined by WHO) was defined as rapidly developing clinical 
signs of focal or global (for patients in coma) neurological deficit lasting more 
than 24 hours or leading to death with no apparent cause other than vascular 
origin. 
 
2. hs-CRP: 
Cut off value for hs-CRP for assessing the prognosis of stroke in this 
study was taken as ≥ 10.1 mg/L and the serum hs-CRP level was correlated with 
the functional recovery of patients after 30 days using the MRS. This was based 
on a study by The 'Bergen stroke study' 
 
3.modified Rankin scale (mRS) 
 
The mRS was utilized to assess the functional outcome and residual 
neurological deficit. 
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The scale runs from 0-6, running from perfect health without symptoms to 
death. 
 0 - No symptoms. 
 1 - No significant disability. Able to carry out all usual activities, despite 
some symptoms. 
 2 - Slight disability. Able to look after own affairs without assistance, but 
unable to carry out all previous activities. 
 3 - Moderate disability. Requires some help, but able to walk unassisted. 
 4 - Moderately severe disability. Unable to attend to own bodily needs 
without assistance, and unable to walk unassisted. 
 5 - Severe disability. Requires constant nursing care and attention, 
bedridden, incontinent. 
 6 - Dead. 
 Score 0,1,2– good outcome  
 Score of 3,4,5 and 6 -poor outcome 
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Risk factors were defined according to protocol 
1.Hypertension (HTN)  
Hypertension (HTN) was defined as treatment with antihypertensive 
drugs before stroke onset or introduction of antihypertensive drugs before 
discharge.  
2.Diabetes mellitus 
Diabetes mellitus (DM) was defined as treatment with   glucose  lowering 
medications or diet prior to stroke onset, or a fasting serum glucose >126 mg/dl  
during hospital stay. 
3. Smoking 
Smoking  was defined as the use of at least one    cigarette     per day 
prior  to stroke onset. 
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MEASUREMENT OF hs-CRP 
 
`The Quantia CRP-US (from Tulip Diagnostics Pvt. Ltd) was used for the 
measurement of hs-CRP. Quantia CRP is a turbidimetric immunoassay for 
ultrasensitive determination of CRP in human serum and is based on the 
principle of agglutination reaction . The test specimen is mixed with quantia 
CRP US latex reagent and activation buffer and allowed to react. Presence of 
CRP in the test specimen results in the formation of an insoluble complex 
producing a turbidity, which is measured at wavelength between 505-578 nm. 
The increase in turbidity corresponds to the concentration of CRP in the test 
specimen. 
   
 
Test procedure: 
  400 microlitre of quantia CRP US activation buffer (R1) was 
pipette out and added to 100 microlitre of Quantia CRP US latex reagent (R2) in 
the measuring cuvette. It was mixed well and incubated for 5 minutes.5 
microlitre of test specimen was added and mixed gently. Absorbance (A1) was 
read exactly at 10 seconds and absorbance (A2) was read again at the end of 
exactly 4 minutes. ΔA (A2-A1) for test specimen was calculated.ΔA gives the 
CRP concentration (‗C‘) of the test specimen.The CRP concentration C was 
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multiplied with the dilution factor (F) of the test specimen for obtaining the 
concentration of CRP in the test specimen. 
 
Concentration of CRP in the test specimen in mg/dl=C x F, 
(where F is the dilution factor of the test specimen) 
 
The quantia CRP US reagent has been designed to measure CRP 
concentrations in the range of 0.015-1.0 mg/dl and is linear within the 
measuring range. 
 
 
Statistical Analysis: 
The statistical methods used for analysis were 
1. Chi- Square test 
2. Sensitivity/Specificity test. 
 
All the analysis was done using Windows-based SPSS statistical package 
(Version 11.5).          
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          RESULTS AND ANALYSIS  
Total number of subjects included in the study = 50 
Number of males    =29(58%) 
Number of females =21(42%) 
 
Table 5: Age of individuals 
 Number 
of 
Cases 
Mean SD Std. 
Error 
Mean 
Minimum 
age 
Maximum 
age 
Age  50 55.56 8.389 1.186 40 69 
 
Mean age of individuals studied =55.56±8.389 
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Table 6: Time of sample collection 
 Number 
of 
Cases 
Mean SD Std. 
Error 
Mean 
Minimum  
Time 
Maximum 
time 
Time of 
collection(hrs) 
50 21.48 10.61 1.5 6 42 
 
Mean time of sample collection  =21.48±10.61 
 
Mean time collected within 24 hrs in our study 
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Table 7: CRP and S. Cholesterol levels 
 
Sl.no Marker  No.Of.Cases Mean  SD Std 
Error 
Mean 
95% 
Confidence 
Interval Of 
Difference 
lower upper 
1. Sr.chol 50 205.78 35.05 4.96 196.50 226.70 
2. hsCRP 50 30.06 21.25 3.005 26.45 34.56 
 
Mean serum cholesterol level in these patients was 205.78 mg/dL 
Mean hs-CRP level was 30.06 mg/L 
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Table 8: hs-CRP vs Age group 
 
Age group 
(YRS) 
hsCRP mg/l TOTAL 
<10.1 >10.1 
40-50 7(14%) 9(18%) 16(32%) 
51-60 3(6%) 17(34%) 20(40%) 
61-70 4(8%) 10(20%) 14(28%) 
TOTAL 14(28%) 36(72%) 50(100%) 
 
Table 9: hs-CRP Vs Sex 
SEX hsCRP mg/l TOTAL 
<10 >10 
MALE 11(22%) 18(36%) 29(58%) 
FEMALE 3(6%) 18(36%) 21(42%) 
TOTAL 14(28%) 36(72%) 50(100%) 
 
 
hsCRP showed no significant relation with gender and age 
group. 
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Table 10: hs-CRP Vs Smokers 
 
P=0.424  NOT SIGNIFICANT 
Smoker and non-smoker from our study found to be at equal risk. 
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Table 11: hs-CRP Vs Alcoholics 
 
 
   P=0.065  NOT SIGNIFICANT 
Alcoholics not associated with elevated hsCRP levels. 
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Table 12: hs-CRP Vs Hypertension 
 
 
P=0.877  NOT SIGNIFICANT 
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Table 13: hs-CRP Vs Diabetics 
 
 
P=0.148 NOT SIGNIFICANT 
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Table 14: hs-CRP Vs mRS Group 
 
 
P= 0.002 SIGNIFICANT 
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Table 15: hs-CRP Vs NIHSS Group 
 
 
P= 0.001 SIGNIFICANT 
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DISCUSSION 
 
The correlation between hs-CRP levels measured within 48 hours of 
onset of stroke to that of the functional outcome of the patient at the end of 30 
days (using mRS) was carried out. 
 
Out of the 50 cases enrolled in the study, 37 cases (74%) had CRP values 
> 10.1 mg/L and 13 cases (26%) had CRP < 10.1 mg/L. 
 
Out of the 37 cases with CRP > 10.1 mg/L  33 cases(66%) associated 
with poor outcome 4 cases (8%) associated with favourable outcome. 
 
On the other hand, of the remaining 13 cases with CRP < 10.1 mg/L,none 
had poor outcome all 13 (26%) had favourable outcome. 
 
Out of the 50 patients, 1 died who had very high hs-CRP levels. Thus 
patients with CRP levels < 10.1 mg/L had a relatively favourable outcome 
(mRS score of 0,1, 2) when compared to patients with levels > 10.1 mg/L (mRS 
score of 3,4,5and 6). 
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So, in our study, the correlation between hs-CRP levels within 
48 hours of onset of ischemic stroke and the prognosis of the cases at the end of 
30 days was statistically significant, the p value for hs-CRP being 0.001 
 
This is consistent with the various studies conducted using hs-CRP as a 
prognostic indicator of acute ischemic stroke. 
 Table 16: Studies conducted using hs-CRP as a prognostic indicator 
 
SL.NO STUDY YEAR 
1 The 'Bergen stroke study' 2009 
2 Mitchell S V Elkind et al 2006 
3 Ufuk Emre et al 2007 
4 Di Napoli et al 2005 
5 Winbeck K et al 2002 
 
The major difference between our study and those of other studies 
mentioned above was that our study involved only hs-CRP levels and not other 
acute phase reactants like fibrinogens. Also, in our study we assessed the 
outcome of patients with acute ischemic stroke at the end of four weeks and not 
at the end of one year. Also, we measured the CRP levels only within 48 after 
the onset of ischemic stroke and not at the end of four weeks or at the time of 
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discharge. This was because of the cost involved in the measurement of hs-
CRP. The other reason, why our study did not have significant correlation with 
age, sex, DM, IHD was that our study sample size was very small. 
 
Out of the 37 cases with CRP > 10.1 mg/L 31 cases (62%) had admission 
NIHSS >7 and 6 cases(12%) had NIHSS <7. On the other hand, of the 
remaining 13 cases with CRP < 10.1 none had admission NIHSS>7. 
   
Diabetes had no statistical significance with hs-CRP in our study. This is 
in contrast to many of the previous studies. This may be because of the small 
sample size and also because of the fact that our study included only acute 
ischemic stroke patients; it was not done exclusively on diabetic subjects. 
   
In our study, total serum cholesterol did not have statistically 
significant correlation with hs-CRP levels. This is in contrast to a study 
conducted by So Yeon Ryu et al in 2005. A limitation of our study was that 
only total serum cholesterol was estimated and not the complete lipid profile. 
 
  In our study, smoking and alcohol had no statistical significance 
with hs-CRP levels. Also age and sex had no statistical significance with hs-
CRP levels. 
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As CRP was found to be an independent risk indicator of further 
cardiovascular and neurovascular events as shown by the subset of Framingham 
study, routine CRP screening of susceptible population like chronic smokers 
and sibilings and first degree relatives of patients with IHD and stroke may 
prove a valuable indicator for predicting future atherothrombotic events and 
then it can be assessed as a routine indicator for aspirin prophylaxis. Thus CRP 
measurements may be helpful in grading patients into high risk and low risk 
category for predicting future cardiovascular and neurovascular events. 
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CONCLUSION 
 
Patients with elevated hs-CRP had a poorer outcome when compared 
to patients with lower levels of CRP, 30 days after the onset of ischemic stroke. 
Patients with elevated hs-CRP had a poor admission NIH stroke 
score>7. 
 
• hs-CRP levels showed no significant correlation in patients with high blood 
pressure. 
• hs-CRP levels had no significant correlation with age or gender. 
• hs-CRP did not show a statistically significant correlation with smoking or 
cholesterol intake. 
 There was no statistically significant correlation between hs-CRP levels and 
those with diabetes. 
 hs-CRP is 100% sensitive and 86.14% specific as a prognostic tool in acute 
ischemic stroke. hs-CRP has a diagnostic accuracy of 94% in patients with 
acute ischemic stroke. 
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1 PASUPARAJ 65 1 16 0 0 1 0 180 24.8 1 3 1 2 0 
2 KALIMUTHAN 50 1 20 1 0 0 0 220 11.1 1 4 1 11 1 
3 NAZEER AHMED 50 1 12 1 1 1 0 216 58.6 1 5 1 11 1 
4 DHARMALINGAM 62 1 26 1 1 0 0 160 9.1 0 3 1 3 0 
5 SELVAMARY 53 2 10 0 0 1 1 220 74.2 1 4 1 12 1 
6 MUNIYAMMAL  58 2 42 0 0 1 1 306 42.33 1 3 1 9 1 
7 SUBRAMANI 60 1 36 1 1 0 1 178 5.6 0 1 0 3 0 
8 ANNADURAI 40 1 22 1 1 0 0 260 49.4 1 3 1 9 1 
9 ANNAKILI 53 2 28 0 0 0 1 250 53.6 1 3 1 12 1 
10 LAKSHMI 54 2 8 0 0 1 0 160 8.16 0 1 0 4 0 
11 PERIYASAMY 60 1 10 1 1 1 0 190 17.7 1 3 1 8 1 
12 RAMAN 50 1 30 1 1 1 0 196 6 0 1 0 3 0 
13 KARUPPAN 50 1 18 1 1 0 0 198 25.2 1 4 1 9 1 
14 XAVIER 45 1 26 0 1 1 0 126 3.4 0 1 0 2 0 
15 FATHIMA 60 2 32 0 0 0 1 286 20.8 1 3 1 10 1 
16 MARIYAMMAL 55 2 15 0 0 1 1 256 58.2 1 4 1 9 1 
17 PODUM PONNU 53 2 10 0 0 0 0 180 5.6 0 1 0 4 0 
18 VEERAMANI 51 1 22 1 1 1 1 189 83 1 5 1 13 1 
19 MADALAIMUTHU 55 1 16 1 1 0 0 280 71.09 1 6 1 14 1 
20 CHINNASAMY 60 1 38 0 0 0 1 190 13.4 1 2 0 4 0 
21 UMA 67 2 9 0 0 1 0 230 25.2 1 4 1 10 1 
22 KALYANI 68 2 24 0 0 0 1 216 48.1 1 4 1 9 1 
23 ABDUL HAMEED 66 1 40 0 0 1 1 208 10 0 3 1 4 0 
24 RAJKUMAR 40 1 16 1 1 0 0 198 7.1 0 1 0 3 0 
25 KANDASAMY 68 1 20 1 1 1 1 198 26.2 1 3 1 8 1 
26 SEKAR 46 1 25 1 1 0 0 190 35.6 1 2 0 5 0 
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27 CHINATHAMBI 65 1 32 1 0 0 1 220 35.4 1 3 1 9 1 
28 AROKYAMARY 60 2 18 0 0 1 1 240 50.1 1 4 1 12 1 
29 SANGEETHA 50 2 30 0 0 1 0 200 40.6 1 3 1 10 1 
30 MEENAMBAL 62 2 42 1 0 1 1 260 62.3 1 4 1 12 1 
31 MAHALINGAM 65 1 34 1 0 1 0 210 35.1 1 3 1 10 1 
32 RAJASEKARAN 48 1 8 1 1 0 1 190 37.1 1 3 1 9 1 
33 LEELA 50 2 12 0 0 0 1 210 4.2 0 1 0 4 0 
34 BALAKRISHNAN 60 1 38 1 0 1 1 190 39.43 1 3 1 11 1 
35 NALLU 41 1 26 1 1 0 0 180 8.3 0 1 0 8 1 
36 SUBRAMANI 40 1 6 1 1 0 0 206 6.7 0 1 0 2 0 
37 RAJALINGAM 62 1 14 1 0 1 1 156 2.88 0 1 0 5 0 
38 CHELLAM 68 2 28 0 0 0 0 256 25.2 1 3 1 6 0 
39 LEELAVATHY 61 2 34 0 0 1 0 180 26.1 1 1 0 3 0 
40 SUNDARI 59 2 20 0 0 0 1 210 25.2 1 3 1 9 1 
41 THANGAMANI 56 1 38 1 1 0 0 180 26.96 1 1 0 4 0 
42 CHINNAYAN 65 1 8 1 1 1 0 186 4.9 0 1 0 3 0 
43 KARUTHAVANAM 56 2 12 0 0 1 0 186 11.68 1 3 1 10 1 
44 RASU 60 1 21 1 1 1 1 190 19.9 1 4 1 13 1 
45 THOMAS 40 1 28 1 1 0 0 176 70.6 1 4 1 11 1 
46 MANICKAM 56 1 12 1 0 0 1 200 31.8 1 3 1 9 1 
47 THILAGAVATHY 69 2 12 0 0 0 1 212 41.6 1 3 1 8 1 
48 MEENAKSHI 42 2 8 0 0 1 0 166 25.2 1 3 1 11 1 
49 AMBIGA 49 2 10 0 0 0 1 194 33.2 1 3 1 10 1 
50 SELVI 55 2 12 0 0 0 1 210 45.1 1 4 1 13 1 
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CLINICAL  SEVERITY  AND  OUTCOME  IN ASSOCIATION WITH 
hsCRP LEVELS IN ACUTE ISCHEMIC STROKE 
PROFORMA 
 
NAME:                                               I.P.NO:                                      
AGE: 
SEX: 
OCCUPATION:     ADDRESS: 
PRESENTATION: 
 
 
PAST H/O: 
  DM- YES/NO    ARTHRITIS- YES/NO 
  HT- YES/NO    NSAID INTAKE- YES/NO 
  CAD- YES/NO    TIA/CVA – YES/NO 
PERSONAL H/O: 
  SMOKING- YES/NO 
  ALCOHOL- YES/NO 
CLINICAL EXAMINATION: 
GENERAL EXAMINATION: 
VITALS:   PR-   /MIN   BP-      MM HG 
CVS: 
RS: 
ABDOMEN: 
CNS: 
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INVESTIGATIONS: 
S.NO INVESTIGATION REPORT 
1. COMPLETE HEMOGRAM HB- 
TC- 
DC- 
ESR- 
2. BLOOD SUGAR  
3. BLOOD UREA  
4. SERUM CREATININE  
5. SERUM CHOLESTROL  
6. SERUM ELECTROLYTES  
7. hsCRP  
8. ECG  
9. URINE ROUTINE  
10. CT BRAIN  
 
 
 
OUTCOME AFTER 30 DAYS ( MODIFIED RANKIN SCORE): 
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ABBREVIATIONS 
APP - Acute phase protein 
BP - Blood pressure 
CAHD - Coronary artery heart disease 
CHD - Coronary heart disease 
CI - Confidence Interval 
CRP-US - C-Reactive Protein ultra sensitive 
DM - Diabetes mellitus 
hs-CRP - High sensitivity C-Reactive Protein 
HT - Hypertension 
IHD - Ischemic heart disease 
IL - Interleukin 
mRS –modified Rankin Scale 
NIHSS-National Institute of Health Stroke score 
mg/L - Milligram/litre 
MI - Myocardial infarction 
m-RNA - Messenger – RNA 
OCP - Oral contraceptive pill 
SAA - Serum amyloid A 
SAP-  Serum amyloid  P 
SAH - Subarachnoid haemorrhage 
SD - Standard deviation 
TIA - Transient ischemic attack 
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LDL-Low Density Lipoprotein 
VLDL- Very low Density Lipoprotein 
Lp(a)- Lipoprotein a 
DALY- Disability Adjusted Life Years 
hsCRP Grp- High sensitivity C-Reactive Protein group  
mRS Grp–modified Rankin Scale group 
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